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Ataxia telangiectasia (AT) is an autosomal recessive
disorder characterized by neuronal degeneration ac-
companied by ataxia, telangiectasias, acute cancer pre-
disposition, and sensitivity to ionizing radiation (IR).
Cells from individuals with AT show unusual sensitivity
to IR, severely attenuated cell cycle checkpoint func-
tions, and poor p53 induction in response to IR com-
pared with normal human fibroblasts (NHFs). The gene
mutated in AT (ATM) has been cloned, and its product,
pATM, has IR-inducible kinase activity. The AT pheno-
type has been suggested to be a consequence, at least in
part, of an inability to respond appropriately to oxida-
tive damage. To test this hypothesis, we examined the
ability of NHFs and AT dermal fibroblasts to respond to
t-butyl hydroperoxide and IR treatment. AT fibroblasts
exhibit, in comparison to NHFs, increased sensitivity to
the toxicity of t-butyl hydroperoxide, as measured by
colony-forming efficiency assays. Unlike NHFs, AT fibro-
blasts fail to show G1 and G2 phase checkpoint functions
or to induce p53 in response to t-butyl hydroperoxide.
Treatment of NHFs with t-butyl hydroperoxide activates
pATM-associated kinase activity. Our results indicate
that pATM is involved in responding to certain aspects
of oxidative damage and in signaling this information to
downstream effectors of the cell cycle checkpoint func-
tions. Our data further suggest that some of the pathol-
ogies seen in AT could arise as a consequence of an
inability to respond normally to oxidative damage.
Ataxia telangiectasia (AT)1 is an autosomal recessive disor-
der characterized by immune disorders, acute cancer predispo-
sition, telangiectasias, sensitivity to ionizing radiation (IR),
and neuronal degeneration (1). The number of individuals who
carry one defective copy of the AT gene has been estimated to
be around 0.5–1% of the general population (2). Those AT
heterozygotes have been reported to exhibit elevated cancer
risk, particularly for breast cancer and lymphoproliferative
disease (3–5). Cultured AT dermal fibroblasts show increased
chromosomal instability and acute sensitivity to IR in compar-
ison to age-matched normal human fibroblasts (NHFs) (6–10).
Cells from individuals with AT exhibit poor p53 induction and
severely impaired G1, S, and G2 phase checkpoint functions in
response to IR (11–14). The gene mutated in AT, ATM, has
been identified (15), and the gene product, pATM, has been
shown to have IR-inducible protein kinase activity (16, 17).
ATM shares homology with the family of phosphatidylinositol
39-kinases (15), which include DNA-PK, ATR, MEC1, TEL1,
TOR, and FRAP among others (18). Members of this family of
proteins have been reported to be involved in various aspects of
the detection of DNA damage and control of cell cycle progres-
sion (18, 19).
pATM has been suggested to function, at least in part, in the
cellular response to oxidative damage (for review see Ref. 20).
Support for this hypothesis comes from observations that
pATM-deficient cells are unusually sensitive to the toxic effects
of hydrogen peroxide, nitric oxide, and superoxide treatment as
determined by colony-forming efficiency assays. Additionally,
they resynthesize glutathione unusually slowly after depletion
with diethyl maleate (21–25). Furthermore, Barlow and col-
leagues (26) have shown that ATM-deficient mice have ele-
vated markers of oxidative stress, particularly in organs such
as the cerebellum, which are consistently affected in individu-
als with AT. Therefore, we hypothesized that pATM-deficient
fibroblasts would lack normal cell cycle checkpoint function in
response to oxidative stress. To test this hypothesis, we com-
pared the effect of IR, and reactive oxygen species produced by
treatment with t-butyl hydroperoxide, on normal and ATM-
deficient human fibroblast strains.
EXPERIMENTAL PROCEDURES
Cell Cultures and Culture Conditions—NHF1 is a normal human
fibroblast culture derived from foreskins of apparently healthy neo-
nates and was used at passages 13–19 (27). GM03349, a normal dermal
fibroblast strain from a 10-year-old male, was obtained from NIGMS
(National Institutes of Health) Human Genetic Mutant Cell Repository
(Camden, NJ) and used at passages 15–19. ATM-deficient dermal fi-
broblasts were obtained from the NIGMS Human Genetic Mutant Cell
Repository (strain designations GM02052 and GM03395 (Camden, NJ))
and the NIA Aging Cell Repository (strain AG03058 (Camden, NJ)).
The donor for the cells of strain GM02052 was a 15-year-old Moroccan
female. Cells of this strain contain a mutation at nucleotide 103 that
causes a change in coding from cysteine to thymidine, resulting in a
stop codon at position 35 (28). The cells of strain GM03395 are dermal
fibroblasts cultured from a skin biopsy of a 13-year-old black male, and
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the cells of strain AG03058 are dermal fibroblasts cultured from a skin
biopsy from a 14-year-old black female. The exact mutations of ATM in
strains GM03395 and AG03058 are not known. However, no pATM
could be detected by immunoblotting in protein extracts from any of
these strains, and the donors expressed the typical phenotype of the AT
disease. These cells were used at passages 14–20. Normal human
fibroblasts (NHF1 and GM03349 strains) were grown at 37 °C in a
humidified 5% CO2 atmosphere in minimum Eagle’s medium, supple-
mented with 10% fetal bovine serum (Life Technologies, Inc.) and 2 mM
glutamine (Life Technologies, Inc.) (NHF medium). ATM-deficient fi-
broblasts (GM02052, GM03395, and AG03058) were grown under the
same conditions in minimum Eagle’s medium supplemented with 20%
fetal bovine serum, 2 mM glutamine, 0.4 mM serine, 0.2 mM aspartic
acid, and 2 mM pyruvic acid (AT medium) (14). HeLa cells, obtained
from the American Type Culture Collection (Manassas, VA), were cul-
tured as above in minimum Eagle’s medium with 5% fetal bovine serum
and 2 mM glutamine. Cells were tested and found to be mycoplasma
free.
Logarithmically growing cell populations in 100-mm plastic dishes
(Becton Dickinson Labware, Franklin Lakes, NJ) were exposed to
g-rays at room temperature using a 137Cs source at a rate of 2.6 Gy/min.
Mock-treated control cells were subjected to the same movements both
in and out of the incubators as treated cells, for both IR and t-butyl
hydroperoxide treatments. When cells were treated with t-butyl hy-
droperoxide, the t-butyl hydroperoxide was added to cell cultures for 15
min. The cultures were then washed 23 with warm media, and the
media were replaced. In experiments where some cell cultures were
treated with t-butyl hydroperoxide, all plates within the same experi-
ment were washed as described above. After treatment, the cells were
incubated for the times indicated and harvested.
Cell Colony-forming Efficiency Assay—Logarithmically growing fi-
broblast populations were harvested by typsinization, counted in a cell
counter (Coulter Counter ZM, Coulter Corp., Miami, Fl), and replated
at a density of 103 fibroblasts/100-mm tissue culture dish. After allow-
ing cells to adhere for 12 h, the fibroblasts were exposed for 15 min to
various concentrations of t-butyl hydroperoxide, washed, and incubated
for 8–12 days in appropriate media. For assays employing mannitol,
fibroblasts were treated 1 h with 1 mM mannitol, followed by treatment
with t-butyl hydroperoxide in the continued presence of 1 mM mannitol,
washed, and incubated as described above. Media were removed and
colonies fixed by the addition of water/methanol (1:1, v/v) containing
crystal violet (1 g/liter) and counted using a dissecting microscope. For
each fibroblast strain, a minimum of two colony-forming assay experi-
ments was performed, with each data point done in triplicate.
Flow Cytometry for G1 Checkpoint Function—G1 checkpoint function
was assayed by flow cytometry using a modification of the cell cycle
analysis protocol in Kastan et al. (1) for simultaneous analysis of DNA
synthesis and cell cycle. Logarithmically growing cells were either
mock-treated, exposed to 3.0 Gy g-IR, or exposed to various concentra-
tions of t-butyl hydroperoxide as described above. 4 h following treat-
ment, BrdUrd (Roche Molecular Biochemicals) was added to the media
to a final concentration of 10 mM, and cells were incubated for an
additional 2 h. Cells were harvested, fixed in phosphate-buffered saline
(PBS)/methanol at a 1:2 (v/v) ratio, and stored at 220 °C. 5 3 105 cells
from each sample were stained for BrdUrd incorporation in a solution of
Tween 20/BSA plus anti-BrdUrd antibody (Becton Dickinson catalog
number 347580) as recommended by the manufacturer. Fluorescein
isothiocyanate-conjugated anti-mouse IgG antibody (Jackson Immu-
noResearch Laboratories, West Grove, PA) was used as secondary an-
tibody. Cells were stained with PBS containing 5 mg/ml propidium
iodide (Roche Molecular Biochemicals) and analyzed using a Becton
Dickinson FACSort. Twenty thousand cells were counted for each anal-
ysis. Flow cytometric experiments were done twice with each treatment
point done in duplicate.
Protein Analysis and Histone H1 in Vitro Kinase Assays—After treat-
ment, cells were harvested and solubilized on ice in kinase lysis buffer
with inhibitors (10 mM sodium phosphate (pH 7.2), 150 mM NaCl, 1%
Nonidet P-40, 1 mM EDTA, 5 mM EGTA, 5 mM b-glycerophosphate, 1
mM dithiothreitol, 120 kallikrein IU/ml aprotinin, and 10 mg/ml leupep-
tin). Protein concentration was determined using a detergent-compat-
ible protein assay kit (Bio-Rad) with bovine serum albumin (BSA) as a
standard. Although the amount of protein used in different kinase
assay experiments varied, within each experiment the protein concen-
trations employed were the same for all samples. In p34CDC2/cyclin B
histone H1 in vitro kinase activity assays 50–100 mg of protein was
used per kinase reaction, whereas 500–700 mg of protein was used per
p33CDK2/cyclin E histone H1 in vitro kinase assay. The desired amount
of protein from solubilized extracts was aliquoted into 1.5-ml microcen-
trifuge tubes, and volumes were adjusted to 500 ml with kinase lysis
buffer. The immunoprecipitations were done with either 0.5 ml of anti-
human cyclin B Powerclonal antibody (catalog number 05-373, Upstate
Biotechnology, Inc., Lake Placid, NY) or 2.0 ml of anti-human cyclin E
Powerclonal antibody (catalog number 05-371, Upstate Biotechnology,
Inc., Lake Placid, NY). Samples were precleared with protein G-agarose
beads (Life Technologies, Inc.), then incubated with the primary anti-
body for 2 h, followed by the addition of protein G-agarose beads. Kinase
reactions were carried out in histone H1 kinase buffer (20 mM HEPES
(pH 7.3), 80 mM b-glycerophosphate, 20 mM EGTA, 50 mM MgCl2, 5 mM
MnCl2, 1 mM dithiothreitol, 60 kallikrein IU/ml aprotinin, 10 mg/ml
leupeptin, 10 mM cyclic AMP-dependent protein kinase-inhibitory pep-
tide), with 8 mg of histone H1 and 10 mCi of [32g-P]ATP (3,000 Ci/mmol,
Amersham Pharmacia Biotech) for 30 min at 37 °C. The kinase reac-
tions were stopped by addition of 23 SDS sample buffer (4% SDS, 150
mM Tris (pH 6.8), 20% glycerol, 1 mM b-mercaptoethanol, 0.02% brom-
phenol blue), and proteins were resolved by 12% SDS-PAGE. Gels were
stained with Coomassie Blue to verify equal histone protein loading,
dried, and subjected to autoradiography with Hyperfilm MP (Amer-
sham Pharmacia Biotech). The radiolabeled protein substrates in the
dried gels were then quantified using a Molecular Dynamics Phosphor-
Imager and ImageQuant software. All kinase assays were performed at
least in triplicate.
Quantification of Mitotic Delay Induced by t-Butyl Hydroperoxide
and IR—After appropriate treatment, fibroblasts were fixed on 100-mm
dishes by the gentle addition of cold methanol. After 10 min the plates
were air-dried and stored at 4 °C until staining with 0.2 mg/ml 49,6-
diamidino-2-phenylindole (DAPI). DAPI-stained cells then were exam-
ined by fluorescence microscopy. The percentage of mitotic cells (the
mitotic index) was determined from counts of a minimum of 5,000 cells.
All mitotic delay treatments were performed in duplicate, and all ex-
periments were done in duplicate.
Protein Analyses—Immunoprecipitations of p53 were performed
with whole cell extracts from five 100-mm tissue culture dishes (;800
mg protein/IP) as described above for protein kinase assays, using 2.5 ml
of anti-p53 murine monoclonal antibody (catalog number OP03, Onco-
gene Research Products, Cambridge, MA) per sample. Eluted proteins
were resolved by 12% SDS-PAGE and transferred to 0.2-mm nitrocel-
lulose membranes. The blots were probed with anti-p53 antibody (a
generous gift from Dr. B. Alex Merrick, NIEHS), which had been raised
in rabbits against immunopurified human r-p53 expressed in a bacu-
lovirus expression system. By using anti-rabbit IgG peroxidase-conju-
gated goat antibody (Roche Molecular Biochemicals), p53 protein was
visualized by chemiluminescence (Pierce) followed by exposure to Hy-
perfilm MP (Amersham Pharmacia Biotech). p53 immunoprecipitations
and Western analysis were performed in triplicate.
To examine the effect of t-butyl hydroperoxide on HO-1 protein levels
in normal and AT fibroblasts, we treated AT and NHF1 fibroblasts with
1–10 mM t-butyl hydroperoxide for 4 h. Cells were then harvested and
lysed as described above; 100 mg of whole cell protein extract was loaded
per lane; proteins were resolved by 12% SDS-PAGE and transferred to
nitrocellulose membranes as described above. Nitrocellulose blots were
probed with anti-HO-1 rabbit polyclonal antibody (catalog number PA3-
019, Affinity Bioreagents, Golden, CO) and visualized using anti-rabbit
IgG peroxidase-conjugated antibody (Roche Molecular Biochemicals) as
described above. All HO-1 induction Western blots were done in
triplicate.
Affinity Purification of pATM Antibody, aATM 7 a.p.—In order to
isolate the highest affinity, highest specificity aATM 7 antibodies from
the rabbit polyclonal antiserum, antibody was affinity-purified using
the original peptide immunogen. Peptide corresponding to pATM resi-
dues 826–840 (ATM-N826 peptide) was immobilized to generate a
peptide column in the following manner. Ten mg of ATM-N826 peptide
were mixed with 1.0 ml of Affi-Gel 15 (Bio-Rad). The reaction mixture
was mixed at room temperature for 2–3 h, and then the organic solvents
were replaced with 10% ethanolamine in water for 1 h at room temper-
ature to terminate the reaction and block any unreacted groups that
remained. The derivatized Affi-Gel was poured into a column and
cleaned by passing 4 M potassium thiocyanate through the packing. The
column was washed with PBS and stored in PBS with 0.02% sodium
azide at 4 °C.
To affinity-purify antipeptide antibody, IgG was isolated from the
whole polyclonal rabbit serum using an Econo-Pac Protein A kit (Bio-
Rad). Twenty five to 30 mg of the protein A-purified IgG was added to
the Affi-Gel peptide column and tumbled overnight at 4 °C. The anti-
body-bound peptide beads were washed with 5 column volumes of 1 M
potassium thiocyanate, and fractions were eluted with 4 M potassium
thiocyanate. BSA (0.1%) was added to peak fractions prior to dialysis in
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13 PBS overnight at 4 °C. The peak fractions were verified by Western
blotting of total protein extracts from normal and ATM-deficient fibro-
blasts that had been resolved by 6% SDS-PAGE (acrylamide/bisacryl-
amide ratio of 100:1). Affinity-purified aATM 7 (aATM 7 a.p.) antibody
was stored in 20% glycerol and 0.02% sodium azide at 220 °C.
pATM in Vitro PHAS-1 Kinase Assay—The pATM in vitro PHAS-1
kinase assays were done as described previously (16, 17). Cells were
incubated for 90 min following exposure with 6.0 Gy g-IR or a 15-min
exposure to 300 mM t-butyl hydroperoxide and then lysed in kinase lysis
buffer with 10 mM b-glycerophosphate and 1 mM NaVO3 added. Cell
lysates were clarified by centrifugation; the protein concentration was
determined; the volume was adjusted to 0.9 ml with kinase lysis buffer
plus inhibitors, and protein G-agarose beads were added to pre-clear
the lysates as described above. After 30 min, the pre-cleared lysates
were removed from the protein G-agarose beads and added to either 0.1
ml of kinase lysis buffer with inhibitors alone or containing aATM 7 a.p.
antibody. In order to test antibody specificity, in some treatments the
aATM 7 a.p. antibody was incubated for 30 min prior to its addition to
the cell lysates with either 25 mg of the peptide that the antibody was
raised against (ATM-N826) or with 25 mg of an irrelevant peptide
sequence of the same length. All pATM kinase reactions were per-
formed at least in triplicate using 1.5–3.0 mg protein lysate per
immunoprecipitation.
Quantification of Thymine Glycol Formation in ATM-normal and
ATM-deficient Fibroblasts after Treatment with t-Butyl Hydroperoxide
and IR—To quantify the damage induced in NHFs and ATM-deficient
fibroblasts by t-butyl hydroperoxide and IR, we measured thymine
glycol formation in the DNA from ATM-normal NHF1 cells and ATM-
deficient AG03058 fibroblasts following treatment by each agent. Six
plates of logarithmically growing NHF1 or AG03058 fibroblasts, at
;70% confluence, were treated with 100 or 300 mM t-butyl hydroperox-
ide or 6 Gy g-IR, as described above. Cells were harvested from each
plate on ice with 5 ml of cold PBS as soon as possible following treat-
ment. The cells were pelleted, washed 1 time in cold PBS, re-pelleted in
1.5-ml microcentrifuge tubes, and quick-frozen in dry ice/ethanol until
assayed. Determination of thymine glycol formation was performed as
described previously (29). Each experimental point was performed in
triplicate.
RESULTS
AT Fibroblast Strains Are Hypersensitive to the Toxic Effects
of t-Butyl Hydroperoxide—To examine the relative toxicity of
reactive oxygen species exposure between normal and pATM-
deficient fibroblasts, we treated different fibroblast strains
with t-butyl hydroperoxide. We employed t-butyl hydroperox-
ide as a source of oxidative stress as it is poorly hydrolyzed by
catalase (30). We reasoned that this is important since catalase
activity has been reported to be low in ATM-deficient cells (31,
32) and thus, using a peroxide that can be hydrolyzed by
catalase, would introduce experimental variation due to differ-
ences in cellular catalase activities.
To initiate these studies, two normal and two ATM-deficient
fibroblast strains were treated with increasing levels of IR, and
toxicity was assayed by colony-forming efficiency. As reported
previously (7), exposure to increasing amounts of IR inhibited
colony formation in ATM-deficient fibroblast strains more ef-
fectively than in NHFs (Fig. 1A). To compare the effects of
t-butyl hydroperoxide on normal and ATM-deficient fibro-
blasts, normal NHF1 and GM03349 cells and ATM-deficient
FIG. 1. ATM-deficient cells are hy-
persensitive to killing following ex-
posures to IR and t-butyl hydroper-
oxide. A, the effect of increasing
concentrations of IR on the colony-form-
ing efficiency of two ATM-normal and two
ATM-deficient fibroblasts. Exponentially
growing fibroblasts were plated at a den-
sity of 103 cells/100-mm plate and allowed
to adhere for 12 h. The cells were then
treated with increasing concentrations of
g-IR and allowed to grow for 8–11 days.
Cell colonies were then stained and
counted. Data indicate survival as a per-
centage of untreated cells. B, the effect of
increasing concentrations of t-butyl hy-
droperoxide on the colony-forming effi-
ciency of two ATM-normal and two ATM-
deficient fibroblast strains. Data indicate
survival as a percentage of untreated
cells. C, the effect of 1 mM mannitol on the
colony-forming efficiency of the ATM-nor-
mal NHF1 and ATM-deficient AG03058
fibroblast stains after exposure to 10 and
100 mM t-butyl hydroperoxide. Data indi-
cate survival as a percentage of untreated
cells.
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GM02052 and GM03395 cells were treated with increasing
concentrations of t-butyl hydroperoxide. As shown in Fig. 1B,
the ATM-deficient fibroblasts were more sensitive to the colo-
ny-forming inhibiting effects of t-butyl hydroperoxide than the
normal fibroblasts. LC50 (lethal concentration for 50% of pop-
ulation) for both normal fibroblast strains was in the 40–50 mM
t-butyl hydroperoxide range, whereas the LC50 for the ATM-
deficient dermal fibroblast strains was in the 6–8 mM range
(Fig. 1B). The colony-inhibiting effect of t-butyl hydroperoxide
in both normal and ATM-deficient fibroblast strains was bipha-
sic, with an initial high sensitivity to low concentrations of
t-butyl hydroperoxide (1–10 mM), followed by less sensitivity at
higher concentrations (.10 mM). This apparent biphasic re-
sponse is pATM-independent and suggests to us that higher
concentrations of t-butyl hydroperoxide induce a pATM-inde-
pendent resistance or adaptive response to the effects of t-butyl
hydroperoxide in both cell types (Fig. 1B, compare 1–10 mM to
10–300 mM t-butyl hydroperoxide).
Peroxides are thought to exert some of their damaging effects
through the production of reactive oxygen intermediates via
events such as the Fenton reaction (for review see Ref. 33). We
pretreated fibroblasts with mannitol for 1 h prior to t-butyl
hydroperoxide treatment in order to ascertain if the colony-
inhibiting effects of t-butyl hydroperoxide could be reduced by
co-treatment with an antioxidant. Mannitol, which is effective
at scavenging hydroxyl radicals (34), was used as an antioxi-
dant. As shown in Fig. 1C, pretreatment with mannitol par-
tially inhibited the killing effect of t-butyl hydroperoxide on
both normal and ATM-deficient fibroblast strains. For most
concentrations examined, the differences between treatment
with and without mannitol are significant. However, pretreat-
ment with mannitol of the ATM-deficient cells showed less
reduction of killing following treatment with the highest con-
centration of t-butyl hydroperoxide (100 mM) (Fig. 1C). This is
likely to be due to the very low number of ATM-deficient cells
that can still form colonies at this concentration of t-butyl
hydroperoxide. Nevertheless, these data show that the toxic
effect of t-butyl hydroperoxide can be partially reversed by
pretreatment with an antioxidant.
Fibroblasts Lacking pATM Function Fail to Exhibit G1 Check-
point Delay in Response to t-Butyl Hydroperoxide Exposure—G1
checkpoint function, as reflected by delay of entry into S phase,
was assayed following exposure to oxidative stress. Exposure of
NHF1 fibroblasts in logarithmic growth phase to t-butyl hy-
droperoxide over a 10–100 mM range resulted in a concentration-
dependent suppression of S phase entry, as measured by flow
cytometry (Table I and Fig. 2). When the ATM-deficient fibro-
blast strain AG03058 was subjected to the same treatment, com-
paratively little inhibition of S phase entry was observed over the
same concentrations of t-butyl hydroperoxide (Table I and Fig. 2).
As demonstrated previously (11, 35), normal fibroblasts exhibit
G1 checkpoint arrest in response to IR, whereas ATM-deficient
fibroblasts did not (Table I and Fig. 2).
p53 protein stabilization and activation, which is necessary
for the elicitation of a full G1 checkpoint response to cellular
damage from IR exposure for more than a transient period
(36–38), is severely attenuated in ATM-deficient cells (35–37).
Since ATM-deficient cells exhibit poor p53 induction in re-
sponse to IR and fail to show a G1 checkpoint function in
response to both IR and t-butyl hydroperoxide treatment, we
hypothesized that p53 induction in response to t-butyl hy-
droperoxide treatment would similarly be poor in AT fibro-
TABLE I
Flow cytometric analysis of ATM-normal NHF1 and ATM-deficient
AG03058 fibroblasts following treatment with increasing
concentrations of t-butyl hydroperoxide (A) and 3.0 Gy IR (B)
Treatment/concentration
Relative percentage of cells in early S phasea
NHF1 (ATM 1/1) AG03058 (ATM 2/2)
A. t-Butyl-OOH
0 mM 100 (68)b 100 (68)
10 mM 100 (67) 104 (610)
30 mM 70 (611) 117 (64)
100 mM 54 (65) 93 (65)
B. g-IR
0 Gy 100 (67) 100 (67)
3.0 Gy 19 (69) 96 (66)
a Percentage of treated cells in early S phase relative to the percent-
age of mock-treated control cells in early S phase.
b 6, standard deviation.
FIG. 2. Flow cytometric analysis of G1 checkpoint delay in
response to t-butyl hydroperoxide exposure and IR treatment in
ATM-normal NHF1 and ATM-deficient AG03058 fibroblasts. Ex-
ponentially growing cells were treated as indicated. Four hours after
treatment, BrdUrd (BrdU) was added for the last 2 h of incubation.
Cells were fixed and stained with a-BrdUrd-fluorescein isothiocyanate
and propidium iodide. Dot plots show incorporation of BrdUrd into DNA
as an indication of DNA synthesis and propidium iodide fluorescence as
an indication of DNA content. The regions drawn represent areas from
which data were taken for analysis.
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blasts compared with NHFs. When p53 immunoprecipitations
were performed, followed by Western blotting with a second
anti-p53 antibody, we found that p53 was induced in NHF1
cells in response to both t-butyl hydroperoxide and IR (Fig. 3).
p53 induction in response to t-butyl hydroperoxide was slower
than induction in response to IR, with significant induction
following IR exposure by 1 h and induction by t-butyl hydroper-
oxide peaking later, ;1–2 h (Fig. 3). At the time points exam-
ined here, neither IR nor t-butyl hydroperoxide treatment sig-
nificantly induced p53 protein levels in the ATM-deficient
fibroblast strain GM02052 (Fig. 3).
p33CDK2/cyclin E-associated kinase activity has been shown
to be required for progression through late G1 and into S phase
(39). To test the effect of t-butyl hydroperoxide on p33CDK2/
cyclin E-associated kinase activity, we treated the NHF1 fibro-
blast strain with either 300 mM t-butyl hydroperoxide or 3.0 Gy
IR, followed by incubation for 1–10 h, and we measured
p33CDK2/cyclin E histone H1 in vitro kinase activity. As shown
in Fig. 4, both treatments resulted in p33CDK2/cyclin E histone
H1 in vitro kinase activity suppression. Maximal inhibition
occurred at 6 h, followed by partial recovery at 10 h. The
inhibition observed following treatment of NHF1 cells with 300
mM t-butyl hydroperoxide was less than that with exposure to
3.0 Gy IR and occurred with delayed kinetics compared with IR
treatment (compare Fig. 4, A and B). When NHF1 cells were
treated with t-butyl hydroperoxide over a 10 mM to 1 mM range
and incubated for 6 h, p33CDK2/cyclin E histone H1 in vitro
kinase activity was found to fall in a concentration-dependent
manner, with kinase activity reduced ;70% at concentrations
of 100 mM t-butyl hydroperoxide and above (data not shown).
When the ATM-deficient dermal fibroblast strain GM02052
was treated with 300 mM t-butyl hydroperoxide or 3.0 Gy,
followed by incubation for 1–10 h, the ATM-deficient fibro-
blasts failed to exhibit significant inhibition of kinase activity
by either agent (Fig. 4, A and B).
t-Butyl Hydroperoxide Exposure Induces a G2 Checkpoint
Response in Normal Fibroblasts That Is Defective in Fibro-
blasts Lacking pATM Function—Exposure of logarithmically
growing cells from the normal fibroblast strain NHF1 to 1.5 Gy
IR resulted in a rapid delay of entry into mitosis 2 h post-
treatment, with a reduction in the mitotic index to only 3%
(610%) that of the mock-treated cells. ATM-deficient fibroblast
cells (GM02052) showed no significant reduction in the mitotic
index relative to mock-treated controls (94 6 2%), in agreement
with previous findings (40). Similarly, exposure of NHF1 cells
to 10–300 mM t-butyl hydroperoxide generated a strong G2
checkpoint response (Fig. 5). Under the same conditions over
the same concentration range of t-butyl hydroperoxide treat-
ment, no significant inhibition of entry into mitosis was ob-
served with the ATM-deficient fibroblast strain cells
(GM02052) 2 h post-treatment (Fig. 5).
To explore further the G2 checkpoint response to t-butyl
hydroperoxide treatment, we performed p34CDC2/cyclin B his-
tone H1 in vitro kinase activity assays on protein extracts from
two normal and two ATM-deficient fibroblast strains. As shown
in Fig. 6A, p34CDC2/cyclin B histone H1 in vitro kinase activity
was suppressed in a concentration-dependent manner 2 h post-
treatment with 1–300 mM t-butyl hydroperoxide in both normal
human fibroblast strains, NHF1 and GM03349. Similarly, ex-
posure to 1.5 Gy IR inhibited p34CDC2/cyclin B histone H1 in
vitro kinase activity from normal human fibroblasts, as we
have previously reported (40, 41) (Fig. 6B). Neither treatment
with t-butyl hydroperoxide at any concentration nor exposure
to 1.5 Gy IR caused the two ATM-deficient fibroblast strains,
GM02052 and GM03395, to display a significant suppression of
p34CDC2/cyclin B histone H1 in vitro kinase activity (Fig. 6, A
and B). A representative p34CDC2/cyclin B histone H1 in vitro
kinase assay for NHF1 and GM02052 fibroblasts is shown in
Fig. 6C.
To investigate the possibility that the ATM-deficient fibro-
blast strains were capable of exhibiting a G2 checkpoint func-
tion but with delayed kinetics in response to exposures of
t-butyl hydroperoxide, a time course analysis of p34CDC2/cyclin
B histone H1 in vitro kinase activity following treatment was
performed. The results indicate that treatment with 300 mM
FIG. 3. Western blot of p53 shows induction in response to
t-butyl hydroperoxide or g-IR treatment in normal and ATM-
deficient fibroblasts. Cells were treated as indicated. p53 was immu-
noprecipitated with an anti-p53 antibody, and SDS-PAGE was per-
formed. The resolved proteins were transferred to nitrocellulose paper
and probed with a second anti-p53 antibody.
FIG. 4. Time course showing the effect of t-butyl hydroperox-
ide and IR treatment on p33CDK2/cyclin E kinase activity in a
normal and ATM-deficient fibroblast strain. Cells in log phase
were exposed for 15 min to 300 mM t-butyl hydroperoxide (A) or exposed
to 3.0 Gy g-IR (B). The cells were then cultured for the indicated times,
lysed, and immunoprecipitated with anti-cyclin E antibody to obtain
p33CDK2/cyclin E protein complexes following the addition of protein
G-agarose beads. p33CDK2/cyclin E kinase activity was measured by in
vitro kinase assay using exogenous histone H1 protein as the substrate
in the presence of [g-32P]ATP. SDS-PAGE was performed to resolve
proteins; the gel was dried, and kinase activity was quantified by
phosphorimaging.
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t-butyl hydroperoxide and exposure to 1.5 Gy IR were both
effective at suppressing p34CDC2/cyclin B histone H1 kinase
activity in NHF1 cells at 1 h post-treatment, with maximal
suppression of kinase activity occurring at 2 h. Activity recov-
ered to roughly untreated levels by 6 h (Figs. 7, A and B). These
kinetics closely resemble those reported previously for the sup-
pression of mitotic entry by 1.5 Gy IR (40). Neither ATM-
deficient fibroblast strain (GM02052 and GM03395) showed
significant suppression of p34CDC2/cyclin B histone H1 in vitro
kinase activity in response to either treatment with 300 mM
t-butyl hydroperoxide or exposure to 1.5 Gy IR at any time
points examined (Fig. 7, A and B). Mannitol pretreatment
reduced the p34CDC2/cyclin B histone H1 in vitro kinase activ-
ity inhibition initiated by 100 mM t-butyl hydroperoxide treat-
ment (data not shown). Thus an antioxidant may partially
reverse the suppressive effects of t-butyl hydroperoxide on the
G2 checkpoint function as indicated by the inhibition of
p34CDC2/cyclin B kinase activity.
t-Butyl Hydroperoxide Treatment Activates pATM-associated
Kinase Activity—IR treatment of melanoma and lymphoblast
cell lines was found to increase pATM-associated kinase activ-
ity toward the PHAS-1 and p53 proteins in in vitro kinase
activity assays (16, 17). IR-inducible kinase activity was found
in pATM normal cell lines but not in cells lines derived from AT
patients. In these studies, pATM kinase activity was reported
to be induced by roughly 2-fold following treatment with IR (16,
17). Based on the data above, we hypothesized that oxidative
damage generated by treatment with t-butyl hydroperoxide
should induce pATM-associated kinase activity.
A rabbit polyclonal antiserum to a peptide corresponding to
pATM residues 826–840 was raised and affinity-purified to the
cognate peptide. Based on Western blot analysis of whole cell
and/or nuclear protein extracts from NHF1 and HeLa cells, it
was determined that the anti-ATM 7 affinity-purified antibody
(aATM 7 a.p.) recognizes a protein of ;350 kDa, the predicted
size of pATM. This band was not detected in dermal fibroblasts
derived from individuals with AT (Fig. 8).
NHF1 cells and the ATM-deficient dermal fibroblast strain
AG03058 treated with either 6.0 Gy IR or 15 min with 300 mM
t-butyl hydroperoxide were examined for pATM kinase activity
90 min following treatment. As shown in Fig. 9A, low levels of
pATM-associated in vitro kinase activity were found to be as-
sociated with immunoprecipitated protein complexes from ex-
tracts from untreated NHFs using the aATM 7 a.p. antibody.
This activity was roughly 50% higher than the background
level of kinase activity associated with protein G-agarose bead
mock immunoprecipitations (using no antibody) with extracts
from IR-treated NHFs. When protein extracts from NHF1 cells
treated with either IR or t-butyl hydroperoxide were assayed
for pATM-associated in vitro kinase activity toward PHAS-1
protein, the level of activity in the immunocomplexes was sig-
nificantly increased. t-Butyl hydroperoxide treatment induced
pATM-associated kinase activity an average of 2.2-fold over the
level found associated with pATM immunocomplexes from un-
treated NHF1 cells in 3 independent experiments. IR treat-
ment increased pATM-associated kinase activity an average of
2.1-fold (average of 6 independent experiments) (Fig. 9A). A
representative pATM kinase assay is shown in Fig. 9B. To
examine the pATM-dependent specificity of these in vitro ki-
nase assays, aATM 7 a.p. antibody was preincubated with
either the peptide that it was raised against (ATM-N826) or an
irrelevant peptide of the same length (data not shown). As
shown in Fig. 9A, the ATM-N826 peptide largely blocked IR-
FIG. 5. Analysis of the delay of mitotic entry following expo-
sure to different concentrations of t-butyl hydroperoxide in the
ATM-normal NHF1 and ATM-deficient GM02052 fibroblasts.
Cells were treated as indicated, fixed by the addition of cold methanol,
and stained with DAPI. The percentage of mitotic cells was counted by
fluorescence microscopy. The results are expressed as the relative mi-
totic index, which is the mitotic index of the treated population ex-
pressed as a percentage of the mitotic index of the mock-treated
population.
FIG. 6. Concentration-response curve showing the effect of
t-butyl hydroperoxide and g-IR treatment on p34CDC2/cyclin B1
kinase activity in two ATM-normal and two ATM-deficient fibro-
blast strains. Cells were harvested for analysis 2 h following treat-
ment with either increasing concentrations of t-butyl hydroperoxide (A)
or 1.5 Gy g-radiation (B). Cyclin B1-associated kinase activity was
analyzed by immunoprecipitation of protein with anti-cyclin B1 anti-
body, followed by in vitro kinase analysis using histone H1 as an
exogenous substrate. C shows a representative p34CDC2/cyclin B1 ki-
nase assay with pATM-normal NHFs and pATM-deficient GM02052
fibroblasts. Proteins were resolved by SDS-PAGE, and incorporation of
g-32P into histone H1 protein was quantified by PhosphorImager
analysis.
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induced pATM-associated in vitro kinase activity to PHAS-1.
Finally, pretreatment with 1 mM mannitol significantly low-
ered t-butyl hydroperoxide-induced pATM-associated kinase
activity toward the PHAS-1 protein (data not shown), indicat-
ing that an antioxidant could reverse the pATM-activating
effects of t-butyl hydroperoxide in this assay.
Further confirmation that the in vitro kinase activity toward
PHAS-1 was associated with pATM was found in that in vitro
kinase activity assayed from protein extracts from fibroblasts
lacking pATM showed no significant difference whether anti-
pATM antibody was present in the assays or not. Furthermore,
with extracts from IR- or t-butyl hydroperoxide-treated ATM-
deficient fibroblasts, the addition of ATM-N826 peptide to the
assay did not suppress the background level of in vitro kinase
activity (Fig. 9B).
Heme Oxygenase-1 Induction Is Normal in AT Fibroblasts—
Heme oxygenase-1 (HO-1) is induced in human skin fibroblasts
by peroxides (42). To determine whether AT fibroblasts were
deficient in this response to oxidative stress, we treated four
fibroblast strains (1 normal and 3 from individuals with AT)
with 0, 1, 3, 10, 30, and 100 mM t-butyl hydroperoxide for 4 h
and performed Western blot analysis for HO-1 protein. As
shown in Fig. 10, t-butyl hydroperoxide treatment resulted in
an induction of HO-1 protein at 10 mM concentrations and
above in all four fibroblast strains. There was no significant
difference in the response of any of the fibroblasts to HO-1
induction. Western blot analyses demonstrated that t-butyl
hydroperoxide maximally induced HO-1 protein at 4–5 h in
each cell type (data not shown). Pretreatment of NHF1 fibro-
blasts with mannitol for 1 h followed by treatment with 10 mM
t-butyl hydroperoxide for 4 h in the continued presence of
mannitol resulted in a significant inhibition of HO-1 protein
induction, demonstrating that an antioxidant could partially
reverse the effects of t-butyl hydroperoxide (data not shown).
Thymine Glycol Formation Induced by t-Butyl Hydroperoxide
Treatment Is the Same in pATM-normal and pATM-deficient
Fibroblasts—NHF1 cells and ATM-deficient fibroblasts
(AG03058) were treated with t-butyl hydroperoxide or IR and
examined for thymine glycol formation. As shown in Table II,
treatment of either fibroblast type with 100 or 300 mM t-butyl
hydroperoxide (A) or 6.0 Gy g-IR (B) resulted in essentially
equal thymine glycol formation between the fibroblast types.
Thus, the initial damage produced by t-butyl hydroperoxide
and IR treatment in pATM normal and deficient fibroblasts is
not significantly different, as measured by thymine glycol
formation.
DISCUSSION
We have examined the role of pATM in cellular responses to
oxidative damage generated by t-butyl hydroperoxide treat-
ment of normal human fibroblasts and ATM-deficient dermal
fibroblasts. We undertook this study for several reasons as
follows. 1) ATM-deficient cells have been reported to be unusu-
ally sensitive to oxidants such as nitric oxide, superoxide, and
hydrogen peroxide in colony-forming efficiency assays com-
pared with normal cells (21, 23–25). 2) ATM-deficient cells
re-synthesize glutathione unusually slowly after depletion with
diethyl maleate (22). 3) Cellular damage by IR exposure has
been suggested to involve damage due to reactive oxygen spe-
cies (43). 4) The RAD9 gene product, which has similar func-
tions to pATM, has been found to be necessary for checkpoint
arrest in response to peroxide exposure (44). 5) BRCA1, which
has been demonstrated to play a role in protecting cells from
damage by hydrogen peroxide (45), has recently been found to
FIG. 7. Time course showing the effect of t-butyl hydroperox-
ide and g-IR treatment on p34CDC2/cyclin B1 kinase activity in
two ATM-normal and two ATM-deficient fibroblast strains. Cells
were exposed to either 300 mM t-butyl hydroperoxide (A) or 1.5 Gy
g-radiation (B) and harvested at the indicated times. Cyclin B1-associ-
ated kinase activity was analyzed using histone H1 as an exogenous
substrate.
FIG. 8. pATM Western analysis. HeLa cells, NHF1 cells, and two
dermal fibroblast strains from individuals with AT were analyzed by
immunoblot analysis for pATM. Whole cell extracts were prepared and
subjected to SDS-PAGE followed by transblotting onto nitrocellulose.
The blots were then probed for pATM using aATM 7 a.p., a rabbit
polyclonal antibody that was peptide affinity-purified.
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be phosphorylated by activated pATM (46). 6) ATM-deficient
mice have been found to have elevated markers of oxidative
damage, such as nitrotyrosine and hemeoxygenase activity, in
organs known to be affected by the AT phenotype. Interest-
ingly, cerebellar HO levels were found to be 600% greater in
ATM-deficient mice than in ATM-normal mice (26). This last
observation is particularly interesting as cerebellar pathologies
are a hallmark of AT (47–49). Finally, pATM has been sug-
gested to function, in part, as a sensor of oxidative stress (20).
We report that compared with pATM normal fibroblasts,
ATM-deficient fibroblasts exhibit the following characteristics
after oxidative damage: 1) greater sensitivity to the toxic effects
of t-butyl hydroperoxide treatment in colony-forming efficiency
assays; 2) failure to delay late G1 phase progression, as meas-
ured by flow cytometry; 3) failure to exhibit G1 checkpoint
function, as measured by inhibition of p33CDK2/cyclin E-asso-
ciated in vitro kinase activity; 4) failure to induce p53; 5) failure
to exhibit inhibition of p34CDC2/cyclin B histone H1 in vitro
kinase activity; and 6) failure to delay entry into mitosis. Also
t-butyl hydroperoxide stimulates pATM-associated kinase ac-
tivity. Thus, in response to oxidative damage, ATM-deficient
cells appear to lack many critical cell cycle checkpoint re-
sponses, in a similar manner to that observed with IR-induced
damage (for review see Ref. 33).
In contrast to these findings, HO-1 protein induction in re-
sponse to t-butyl hydroperoxide appeared normal in ATM-de-
ficient fibroblasts, indicating that some cellular responses to
oxidative damage are regulated normally in ATM-deficient
cells. Similarly, both ATM-deficient and -normal cells exhibited
a biphasic response in colony-forming efficiency assays, with an
initial sensitivity to low concentrations of t-butyl hydroperox-
ide (1–10 mM), followed by lesser sensitivity at higher concen-
trations (.10 mM). Whereas ATM-deficient fibroblasts were
clearly more sensitive to the colony-forming inhibitory effects of
t-butyl hydroperoxide, the appearance of the biphasic response
in both normal and AT cells suggests that higher concentra-
tions of t-butyl hydroperoxide (.10 mM) induce a resistance to
the effects of t-butyl hydroperoxide that is both pATM-inde-
pendent and similar to that seen in normal cells. The biphasic
colony-inhibitory response we found here is similar to one
reported with mouse embryonic stem cells exposed to hydrogen
peroxide (45), suggesting that this biphasic response may be a
common adaptive event following peroxide exposure.
One possible interpretation of our findings could be that
ATM-deficient cells may respond normally to oxidative damage
generated by t-butyl hydroperoxide treatment but not exhibit
normal checkpoint responses or p53 induction due to their
receiving less damage than normal fibroblasts after exposure to
the same concentration of t-butyl hydroperoxide. To address
FIG. 9. pATM in vitro kinase assay. A, NHFs (ATM-normal) and
the ATM-deficient dermal fibroblasts AG03058 were treated with either
300 mM t-butyl hydroperoxide or 6.0 Gy g-IR, as indicated, incubated for
90 min, then harvested, and lysed, and protein extracts were subjected
to immunoprecipitation with aATM 7 a.p. antibody. An in vitro kinase
analysis was performed using PHAS-1 protein as an exogenous sub-
strate in the presence of [g-32P]ATP. Error bars in this figure represent
standard deviation in three successive pATM in vitro kinase assays.
The incorporation of g-32P into PHAS-1 protein was quantified by
SDS-PAGE followed by PhosphorImager analysis. B, a representative
pATM in vitro kinase assay used to generate figure A. The relative
values of each data point are as follows: 1st lane, 1.00 6 0; 2nd lane,
1.55 6 0.19; 3rd lane, 3.24 6 1.54; 4th lane, 3.35 6 0.90; 5th lane, 1.46 6
0.75; 6th lane, 1.00 6 0; 7th lane, 1.08 6 0.33; and 8th lane, 1.02 6 0.27,
where assays with extracts from g-irradiated cells plus protein G-
agarose beads without any antibody were set at 1.00 in each
experiment.
FIG. 10. Western blot analysis of heme oxygenase induction in
response to t-butyl hydroperoxide treatment. One normal and
three ATM-deficient fibroblast strains were treated as indicated; whole
cell lysates were prepared, and protein extracts were subjected to SDS-
PAGE. The resolved proteins were then transblotted onto nitrocellulose
and probed using an anti-heme oxygenase antibody.
TABLE II
Thymine glycol formation in ATM-normal NHF1 and ATM-deficient
AG03058 fibroblasts following treatment with 100 and 300 mM t-butyl
hydroperoxide and 6.0 Gy g-IR
Treatment/concentration
Thymine glycol/107 basesa
NHF1 (ATM 1/1) AG03058 (ATM 2/2)
A. t-Butyl-OOH
0 mM NDb ND
100 mM 19 (63)c 20 (62)
300 mM 60 (64) 58 (64)
B. g-IR
6.0 Gy 5.5 (60.3) 5.5 (60.2)
a Cells were harvested immediately after treatment and quick-frozen
until analysis. Thymine glycol quantification was performed as re-
ported previously (29).
b ND, not detectable.
c 6, standard deviation.
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this issue we quantified DNA damage induced by IR and t-
butyl hydroperoxide exposure by quantifying thymine glycol
formation in normal and ATM-deficient fibroblasts. We found
that thymine glycol formation was not significantly different
between the fibroblast types directly following exposure to ei-
ther agent. Based on these data, we conclude that the initial
damage received by normal and ATM-deficient fibroblasts fol-
lowing IR and t-butyl hydroperoxide exposure is approximately
the same and that, in fact, it is the absence of pATM function
that accounts for the differences seen between the cells types.
A major hallmark of cells from individuals with AT is the
ablation of the G1, S, and G2 checkpoint functions in response
to IR, as well as other IR response-related events, such as p53
and p21 induction (11, 12, 36, 37, 50). Here we have shown that
after exposure to t-butyl hydroperoxide, ATM-deficient fibro-
blasts lack G1 and G2 checkpoint responses, lack p53 induction,
and show enhanced toxicity, reminiscent of the cellular re-
sponses seen with ATM-deficient fibroblasts exposed to IR.
Thus our data support the hypothesis that pATM plays a role
in resistance to oxidative stress (20).
Cell cycle checkpoints are thought to function, in part, to
allow cells time to repair damage, particularly damage to DNA,
before re-entering the cell cycle and completing subsequent
cellular events such as DNA replication or mitosis. Ablation of
cellular checkpoint functions, such as occurs in ATM-deficient
cells or in cells treated with methylxanthines, can result in
greater lethality following exposure to toxic agents (for review
see Ref. 33). One question we have not addressed is whether or
not pATM responds to oxidative damage to DNA or responds
directly to a change in intracellular redox state independent of
DNA damage. Although our data do not address this question
specifically, we do demonstrate that ATM-deficient fibroblasts
fail to exhibit normal G1 and G2 checkpoint responses following
exposure to oxidative stress. Thus the inability of ATM-defi-
cient cells to exhibit G1 and G2 checkpoint responses following
oxidative damage is likely to be one mechanism that predis-
poses these cells to enhanced toxicity in response to exposure to
oxidative stress. Our results suggest that there is an inability
to respond to oxidative stress in cells from individuals with AT,
a consequence of which may be relevant to the mechanisms of
Purkinje cell death and other pathological changes observed in
AT patients.
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